<DOC>
	<DOCNO>NCT02603497</DOCNO>
	<brief_summary>The objective study compare pharmacokinetics ASP015K patient impair renal function subject normal renal function .</brief_summary>
	<brief_title>Pharmacokinetics Study Patients With Impaired Renal Function Subjects With Normal Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>All subject Body weight ) : ≥40.0 kg &lt; 90.0 kg Body mass index BMI : ≥17.6 &lt; 30.0 Female subject must either : Be postmenopausal surgically sterile . Agree try become pregnant starting time inform consent throughout study period 60 day final study drug administration childbearing potential . Female subject agree breastfeed start informed consent throughout study period 60 day final study drug administration Agree donate ovum female / sperm male start informed consent throughout study period 60/90 day final study drug administration Agree use highly effective contraception Patients impaired renal function Patients eGFR GFR predictive equation Japanese within follow range screen undergoing dialysis . Patients mild impaired renal function ( eGFR ; ≥60 mL/min/1.73 m2 &lt; 90 mL/min/1.73 m2 ) Patients moderate impaired renal function ( eGFR ; ≥30 mL/min/1.73 m2 &lt; 60 mL/min/1.73 m2 ) Patients severe impaired renal function ( eGFR ; ≥15 mL/min/1.73 m2 &lt; 30 mL/min/1.73 m2 ) Patients whose treatment regimen ( include diet ) renal impairment complication remain unchanged within 14 day prior hospital admission day ( Day 1 ) , patient receive treatment ( include diet ) need change period 14 day hospital admission day ( Day 1 ) followup examination opinion investigator subinvestigator . Subjects normal renal function Subjects eGFR GFR predictive equation Japanese ≥ 90 mL/min/1.73 m2 screen Subjects healthy , judged investigator subinvestigator base physical examination ( subjective symptom objective finding ) test obtain screen period hospital admission immediately study drug administration All subject Received schedule receive study drug clinical trial postmarketing study within 120 day screen period screen hospital admission day ( Day 1 ) Deviate follow provided range blood pressure , pulse rate , body temperature standard 12lead ECG screen hospital admission day ( Day 1 ) Subjects meet criterion laboratory test screen hospital admission day ( Day 1 ) . Normal range test specify study site test/assay organization use normal range study . Complication history drug allergy Developed upper gastrointestinal symptom within 7 day hospital admission day ( Day −1 ) Complication history hepatic disease Complication long QT syndrome , congenital short QT syndrome A history gastrointestinal resection Subjects complication history endocrine disease Subjects complication history malignant tumor Subjects complication history lymphatic disease Applies follow concern tuberculosis A history active tuberculosis Abnormalities detect chest Xray test ( screen ) Contact infectious tuberculous patient Applies follow concern , regard infection except tuberculosis A complication history severe herpes zoster herpes zoster disseminate At least twice relapse localized herpes zoster Inpatient hospital care severe infectious disease within 90 day hospital admission day ( Day 1 ) Treatment intravenous antibiotic within 90 day hospital admission day ( Day 1 ) ( prophylactic antibiotic applicable ) . Other , subject high risk develop infectious disease ( e.g . subject urethral catheterisation ) judgment investigator subinvestigator . Vaccination live vaccine live attenuate vaccine within 56 day hospital admission day ( Day 1 ) ( Inactivated vaccine influenza vaccine pneumococcal vaccine applicable . ) A history clinically serious allergy Previously receive administration ASP015K Excessive alcohol drink smoking Patients impaired renal function Patients receive scheduled receive new drug within 14 day hospital admission day ( Day 1 ) Patients receive dialysis , receive renal transplantation Patients develop acute change renal function laboratory test result within 28 day screen patient impaired renal function may need new concomitant therapy study period . Patients complication severe heart disease , NYHA class III IV cardiac failure . Complication alimentary disease , cerebrovascular disorder , respiratory disease Patients tubular dysfunction , obvious urination impaired Subjects normal renal function Subjects receive schedule receive medication ( include overthecounter [ OTC ] drug ) within seven day hospital admission day ( Day 1 ) . Subjects complication history heart disease , respiratory disease , alimentary disease , renal disease , endocrine disease , urological disease , cerebrovascular disorder</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ASP015K</keyword>
	<keyword>impaired renal function</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>